Immunovant Inc. is a biopharmaceutical company that was founded in 2016. The company is focused on the development of innovative therapies for autoimmune diseases. Immunovant's mission is to address unmet medical needs in the field of autoimmune disorders by targeting the underlying mechanisms that drive these conditions.
Immunovant is particularly focused on developing treatments that target autoimmune diseases mediated by autoantibodies, which are antibodies that mistakenly attack the body's own tissues. The company's lead product candidate, IMVT-1401, is a fully human monoclonal antibody that binds to a protein called neonatal Fc receptor (FcRn). By targeting FcRn, IMVT-1401 aims to reduce the levels of pathogenic autoantibodies in the body and provide therapeutic benefits for patients with autoimmune diseases.
The company is actively conducting clinical trials to evaluate the safety and efficacy of IMVT-1401 in various autoimmune diseases, including myasthenia gravis and warm autoimmune hemolytic anemia. Immunovant is committed to advancing its pipeline of novel therapies and bringing new treatment options to patients suffering from autoimmune conditions.
In terms of its public status, Immunovant went public on October 25, 2019. The company completed its initial public offering (IPO) and began trading on the Nasdaq Stock Market under the ticker symbol "IMVT." Going public has provided Immunovant with additional financial resources to support its research and development efforts and further advance its pipeline of potential therapies.